Drug updated on 11/15/2023
|Capsule (oral; 25 mg, 100 mg),Oral Solution (oral; 20 mg/mL)
| Ongoing and
- For the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation.
- For the treatment of adult and pediatric patients with solid tumors that are metastatic or where surgical resection is likely to result in severe morbidity.
- For the treatment of adult and pediatric patients with solid tumors that have no satisfactory alternative treatments or that have progressed following treatment.
Product Monograph / Prescribing Information
|Vitrakvi (larotrectinib) Prescribing Information.
|Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
Systematic Reviews / Meta-Analyses
|Combined clinical and pharmacoeconomic report: larotrectinib (Vitrakvi).
|Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.
|Current medical research and opinion
|Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy.
|Assessment report: Vitrakvi.
Clinical Practice Guidelines
|Metastatic pancreatic cancer: ASCO guideline update.
|Journal of Clinical Oncology